title: Incubation of nicotine seeking is associated with enhanced protein kinase A-regulated signaling of dopamine- and cAMP-regulated phosphoprotein of 32 kDa in the insular cortex.
abstract: A recent clinical study demonstrated that damage to the insular cortex can disrupt tobacco addiction. The neurobiological mechanisms for this effect are not yet understood. In this study we used an animal model of nicotine addiction to examine the possibility that changes in insular cortex levels of dopamine (DA)- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), a phosphoprotein enriched in DA neurons containing DA D1 receptors, may be associated with changes in vulnerability to nicotine addiction. Once rats acquired self-administration, they were given unlimited access to nicotine (0.01 mg/kg/infusion) for 23 h/day for a total of 10 days. Each infusion was paired with a visual cue (stimulus light) and auditory cue (sound of pump). Nicotine seeking, as assessed under a cue-induced reinstatement paradigm, and markers of DARPP-32 signaling, as assessed using western blot analysis, were examined in separate groups of rats at two different abstinent intervals: 1 and 7 days. Consistent with findings with other drugs of abuse, rats in the 7-day abstinence group took longer to extinguish and responded at higher levels during reinstatement testing as compared with rats in the 1-day reinstatement group. Relative to saline controls, rats in the 7-day but not the 1-day abstinence group had higher levels of DARPP-32 phosphorylated at the protein kinase A site in the insular cortex. These results demonstrate incubation of drug seeking following extended access to nicotine self-administration and suggest that enhanced protein kinase A signaling in the insular cortex via phosphorylation of DARPP-32 at Thr34 is associated with this effect.
authors.affiliation: Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, 1670 Discovery Drive, Charlottesville, VA 22911, USA.
authors.forename: Amir
authors.initials: A
authors.lastname: Abdolahi
authors.forename: Glen
authors.initials: G
authors.lastname: Acosta
authors.forename: Florence J
authors.initials: FJ
authors.lastname: Breslin
authors.forename: Scott E
authors.initials: SE
authors.lastname: Hemby
authors.forename: Wendy J
authors.initials: WJ
authors.lastname: Lynch
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000378:metabolism*; D002540:Cerebral Cortex / Q000378:metabolism*; D003463:Cues; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D051937:Dopamine and cAMP-Regulated Phosphoprotein 32 / Q000378:metabolism*; D005108:Extinction, Psychological; D008297:Male; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012646:Self Administration; D015398:Signal Transduction / Q000187:drug effects*; D013997:Time Factors
chemical_list: D051937:Dopamine and cAMP-Regulated Phosphoprotein 32; D009538:Nicotine; D017868:Cyclic AMP-Dependent Protein Kinases
references.citation: Eur J Neurosci. 2006 Dec;24(11):3285-98
references.pmid: 17156389
references.citation: Science. 2007 Oct 26;318(5850):655-8
references.pmid: 17962567
references.citation: Psychopharmacology (Berl). 2007 Sep;194(1):103-16
references.pmid: 17541779
references.citation: J Neurosci. 2006 Mar 8;26(10):2645-51
references.pmid: 16525043
references.citation: J Comp Neurol. 1992 Sep 8;323(2):209-18
references.pmid: 1328330
references.citation: Brain Res. 1997 Nov 14;775(1-2):30-6
references.pmid: 9439825
references.citation: Neuropharmacology. 2004;47 Suppl 1:14-23
references.pmid: 15464122
references.citation: Psychopharmacology (Berl). 2008 Feb;196(3):365-75
references.pmid: 17932656
references.citation: Eur J Pharmacol. 2005 Dec 5;526(1-3):36-50
references.pmid: 16289451
references.citation: J Neurosci. 2007 Dec 19;27(51):14035-40
references.pmid: 18094242
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4147-52
references.pmid: 17360491
references.citation: Eur J Neurosci. 2005 Sep;22(5):1214-20
references.pmid: 16176364
references.citation: J Pharmacol Exp Ther. 2005 Nov;315(2):872-8
references.pmid: 16040813
references.citation: Psychopharmacology (Berl). 2003 Oct;170(1):23-32
references.pmid: 12768275
references.citation: J Neurosci. 1999 Aug 1;19(15):6610-4
references.pmid: 10414988
references.citation: Cereb Cortex. 2000 Mar;10(3):318-25
references.pmid: 10731226
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19480-5
references.pmid: 19033203
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references.pmid: 12402102
references.citation: Arch Gen Psychiatry. 1986 Feb;43(2):107-13
references.pmid: 3947206
references.citation: Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12840-5
references.pmid: 11050161
references.citation: Psychopharmacology (Berl). 1997 Oct;133(3):300-4
references.pmid: 9361337
references.citation: Science. 2007 Jan 26;315(5811):531-4
references.pmid: 17255515
references.citation: Neuron. 2005 Mar 3;45(5):647-50
references.pmid: 15748840
references.citation: AAPS J. 2005 Oct 05;7(2):E353-60
references.pmid: 16353915
references.citation: Behav Pharmacol. 2000 Aug;11(5):365-76
references.pmid: 11103888
references.citation: Psychopharmacology (Berl). 2000 Feb;148(2):196-200
references.pmid: 10663435
references.citation: J Comp Neurol. 1990 Sep 15;299(3):327-48
references.pmid: 2229482
references.citation: Nature. 2001 Jul 12;412(6843):141-2
references.pmid: 11449260
references.citation: J Neurosci. 1998 Mar 1;18(5):1848-59
references.pmid: 9465009
references.citation: J Neurosci. 2004 Jul 21;24(29):6600-10
references.pmid: 15269272
references.citation: Nicotine Tob Res. 1999;1 Suppl 2:S133-7; discussion S139-40
references.pmid: 11768171
references.citation: Nature. 2003 Jan 2;421(6918):70-5
references.pmid: 12511956
references.citation: Psychopharmacology (Berl). 2008 Sep;200(1):81-91
references.pmid: 18584153
references.citation: Nature. 2008 Jul 3;454(7200):118-21
references.pmid: 18500330
references.citation: Trends Neurosci. 2009 Jan;32(1):56-67
references.pmid: 18986715
references.citation: J Neurosci. 2003 Feb 1;23(3):742-7
references.pmid: 12574402
references.citation: Psychopharmacology (Berl). 2008 Apr;197(2):237-46
references.pmid: 18066534
references.citation: Neuropharmacology. 2009;56 Suppl 1:177-85
references.pmid: 18565549
references.citation: Neuropsychopharmacology. 2008 Jul;33(8):1807-17
references.pmid: 17851536
references.citation: J Neurosci. 2005 Apr 13;25(15):3932-9
references.pmid: 15829645